|
1.
|
Van der Poel HG and Debruyne FM: Can
biological markers replace cystoscopy? An update Curr Opin Urol.
11:503–509. 2001.PubMed/NCBI
|
|
2.
|
Simon MA, Lokeshwar VB and Soloway MS:
Current bladder cancer tests: unnecessary or beneficial? Crit Rev
Oncol Hematol. 47:91–107. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Giannopoulos A, Manousakas T, Gounari A,
et al: Comparative evaluation of the diagnostic performance of the
BTA stat test, NMP22 and urinary bladder cancer antigen for primary
and recurrent bladder tumors. J Urol. 166:470–475. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Bartel DP: MicroRNAs: genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Calin GA, Sevignani C, Dumitru CD, et al:
Human microRNA genes are frequently located at fragile sites and
genomic regions involved in cancers. Proc Natl Acad of Sci USA.
101:2999–3004. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7.
|
Lu J, Getz G, Miska EA, et al: MicroRNA
expression profiles classify human cancers. Nature. 435:834–838.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Chen CZ: MicroRNAs as oncogenes and tumor
suppressors. N Engl J Med. 353:1768–1771. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Weber JA, Baxter DH, Zhang S, et al: The
microRNA spectrum in 12 body fluids. Clin Chem. 56:1733–1741. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Yamada Y, Enokida H, Kojima S, et al:
MiR-96 and miR-183 detection in urine serve as potential tumor
markers of urothelial carcinoma: correlation with stage and grade,
and comparison with urinary cytology. Cancer Sci. 102:522–529.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Hanke M, Hoefig K, Merz H, et al: A robust
methodology to study urine microRNA as tumor marker: microRNA-126
and microRNA-182 are related to urinary bladder cancer. Urol Oncol.
28:655–661. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Meiri E, Levy A, Benjamin H, et al:
Discovery of microRNAs and other small RNAs in solid tumors.
Nucleic Acids Res. 38:6234–6246. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Jeffrey SS: Cancer biomarker profiling
with microRNAs. Nat Biotechnol. 26:400–401. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Valadi H, Ekstrom K, Bossios A, et al:
Exosome-mediated transfer of mRNAs and microRNAs is a novel
mechanism of genetic exchange between cells. Nat Cell Biol.
9:654–659. 2007. View
Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Skog J, Wurdinger T, van Rijn S, et al:
Glioblastoma microvesicles transport RNA and proteins that promote
tumour growth and provide diagnostic biomarkers. Nat Cell Biol.
10:1470–1476. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Gilad S, Meiri E, Yogev Y, et al: Serum
microRNAs are promising novel biomarkers. PloS One. 3:e31482008.
View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Wang G, Tam LS, Li EK, et al: Serum and
urinary cell-free MiR-146a and MiR-155 in patients with systemic
lupus erythematosus. J Rheumatol. 37:2516–2522. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Ostenfeld MS, Bramsen JB, Lamy P, et al:
miR-145 induces caspase-dependent and -independent cell death in
urothelial cancer cell lines with targeting of an expression
signature present in Ta bladder tumors. Oncogene. 29:1073–1084.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Schaefer A, Stephan C, Busch J, et al:
Diagnostic, prognostic and therapeutic implications of microRNAs in
urologic tumors. Nat Rev Urol. 7:286–297. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Ichimi T, Enokida H, Okuno Y, et al:
Identification of novel microRNA targets based on microRNA
signatures in bladder cancer. Int J Cancer. 125:345–352. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Dyrskjot L, Ostenfeld MS, Bramsen JB, et
al: Genomic profiling of microRNAs in bladder cancer: miR-129 is
associated with poor outcome and promotes cell death in vitro.
Cancer Res. 69:4851–4860. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Friedman JM, Liang G, Liu CC, et al: The
putative tumor suppressor microRNA-101 modulates the cancer
epigenome by repressing the polycomb group protein EZH2. Cancer
Res. 69:2623–2629. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Park SM, Gaur A, Lengyel E and Peter ME:
The miR-200 family determines the epithelial phenotype of cancer
cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes
Dev. 22:894–907. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Korpal M, Lee ES, Hu G and Kang Y: The
miR-200 family inhibits epithelial-mesenchymal transition and
cancer cell migration by direct targeting of E-cadherin
transcriptional repressors ZEB1 and ZEB2. J Biol Chem.
283:14910–14914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Bracken CP, Gregory PA, Kolesnikoff N, et
al: A double-negative feedback loop between ZEB1-SIP1 and the
microRNA-200 family regulates epithelial-mesenchymal transition.
Cancer Res. 68:7846–7854. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Gregory PA, Bert AG, Paterson EL, et al:
The miR-200 family and miR-205 regulate epithelial to mesenchymal
transition by targeting ZEB1 and SIP1. Nat Cell Biol. 10:593–601.
2008. View
Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Bruyere F, Namdarian B, Corcoran NM, et
al: Snail expression is an independent predictor of tumor
recurrence in superficial bladder cancers. Urol Oncol. 28:591–596.
2010. View Article : Google Scholar : PubMed/NCBI
|
